Posted: 1 May 2024 A research project supported by BioCurate’s Proof of Concept fund led by Monash University will move into the next exciting phase as an exclusive licence in the BioCurate Portfolio. The research, led by Monash…
Posted: 1 May 2024 Patients at the new Paula Fox Melanoma and Cancer Centre at Melbourne’s Alfred Hospital will have access to cutting-edge scanning technology that will be able to detect cancers earlier. The Albanese Government is investing…
Posted: 1 May 2024 A clinical trial led by a Peter Mac medical oncologist has demonstrated the benefits of a new lung cancer treatment, and these practise-changing results have just published in the New England Journal of Medicine.…
Posted: 1 May 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces preliminary topline results from Cohort B of the TACTI-003…
Posted: 1 May 2024 New research published today in the journal Cellular and Molecular Gastroenterology and Hepatology sheds light on disease mechanisms common to irritable bowel syndrome (IBS) and cardiovascular diseases (CVD). Led by Dr Leticia Camargo Tavares, a Postdoctoral Fellow…
Posted: 1 May 2024 INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce the successful completion of an analytical validation study for its blood test for ovarian cancer. Overall, the test correctly identified 85% of all samples tested…
Posted: 1 May 2024 The Cook Government is providing $425,000 for the ongoing support of Western Australia’s industry training in the health and medical life sciences sector. Medical Research Minister Stephen Dawson welcomed the funding boost to support…
Posted: 1 May 2024 Pathios Therapeutics Limited (“Pathios”), a biotech company focused on the development of first-in-class therapies for cancer, today announced that the company has raised $25 million in the first close of a Series B financing.…
Posted: 1 May 2024 ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, announces today that the U.S. Food and Drug Administration (‘FDA’) has…
Posted: 1 May 2024 Today, on World Liver Day, Gilead Sciences Australia has announced nine local community organisations addressing viral hepatitis will receive a combined AU$400,000 via the global Gilead ALL4LIVER Grant. The recipients were selected by an…
Posted: 26 April 2024 Following the success of our operation in Melbourne, we are pleased to open a second branch in Brisbane to better serve the local area. The new office is located close to Brisbane airport which…
Posted: 29 April 2024 Three extraordinary women, who are driving change in the healthtech industry, are recipients of 2024 BioMelbourne Network Women in Leadership Awards. These innovators are entrepreneurs who are inspiring the next generation of scientists and…